



September 15, 2026

Company Name	Nojima Corporation
Representative	Hiroshi Nojima, Director and Representative Executive Officer & President (Code: 7419, Tokyo Stock Exchange, Prime Market)
Contact	Hajime Nukumori, Director and Representative Executive Officer & Vice President TEL : +81-50-3116-6500

(Correction) Partial Correction to the "Notice Regarding the Grant of Stock Options (Share Acquisition Rights) and the Terms of Issuance, etc."

Nojima Corporation (the "Company") hereby announces that it has corrected certain items stated in the "Notice Regarding the Grant of Stock Options (Share Acquisition Rights) and the Terms of Issuance, etc." announced on July 21, 2026.

For the background of the correction and the Company's response going forward, please refer to the "Notice Regarding the Change of the Allotment Date, etc. of Stock Options (Share Acquisition Rights)" separately announced today.

1. Reason for the Correction

It was discovered that, with respect to the portion granted to the employees of the Company and the employees of its subsidiaries, the period for giving notice to the shareholders prescribed in Article 240, Paragraph 2 of the Companies Act had not been satisfied. Accordingly, at a meeting of the Board of Directors held today, the Company resolved to change the allotment date, among other matters constituting the subscription requirements of the Share Acquisition Rights. In addition, in connection with changes in the persons to be allotted, the Company corrects the number of Share Acquisition Rights to be issued and the number of persons to be allotted with respect to the portion granted to the employees of the Company and the employees of its subsidiaries.

2. Details of the Correction

Corrected portions are underlined.

(4) Outline of the issuance of the Share Acquisition Rights

<Corrections common to (i) and (ii)>

(i) Outline of the issuance to the Directors and Executive Officers of the Company and the Directors, Corporate Auditors and Operating Officers of the Company's subsidiaries

(ii) Outline of the issuance to the employees of the Company and the employees of its subsidiaries

<Before correction>

1. Issue date of the Share Acquisition Rights: August 4, 2026

5. Amount to be paid in upon exercise of the Share Acquisition Rights: To be determined (scheduled to be determined on August 4, 2026)

6. Total issue price of the shares to be issued upon exercise of the Share Acquisition Rights: To be determined (scheduled to be determined on August 4, 2026)

7. Exercise period of the Share Acquisition Rights: From July 22, 2029 to July 21, 2031

<After correction>

1. Issue date of the Share Acquisition Rights: October 5, 2026

5. Amount to be paid in upon exercise of the Share Acquisition Rights: To be determined (scheduled to be determined on October 5, 2026)

6. Total issue price of the shares to be issued upon exercise of the Share Acquisition Rights: To be determined (scheduled to be determined on October 5, 2026)

7. Exercise period of the Share Acquisition Rights: From September 16, 2029 to September 15, 2031

<Correction to (ii) Outline of the issuance to the employees of the Company and the employees of its subsidiaries>

<Before correction>

2. Number of Share Acquisition Rights to be issued: 96,785 rights (100 shares per Share Acquisition Right)

9. Number of persons to be allotted: 1,519 employees of the Company; 3,282 employees of the Company's subsidiaries

<After correction>

2. Number of Share Acquisition Rights to be issued: 96,427 rights (100 shares per Share Acquisition Right)

9. Number of persons to be allotted: 1,491 employees of the Company; 3,275 employees of the Company's subsidiaries

Note that, with respect to (i) Outline of the issuance to the Directors and Executive Officers of the Company and the Directors, Corporate Auditors and Operating Officers of the Company's subsidiaries, "2. Number of Share Acquisition Rights to be issued" (17,280 rights) and "9. Number of persons to be allotted" (15 Directors of the Company, 5 Executive Officers of the Company, 28 Directors of the Company's subsidiaries, 5 Corporate Auditors of the Company's subsidiaries and 26 Operating Officers of the Company's subsidiaries) are not corrected.

(7) Exercise period of the Share Acquisition Rights

<Before correction>

The exercise period shall commence on the date on which three years have elapsed from the day following the date of the resolution of the Board of Directors determining the subscription requirements of the Share Acquisition Rights, and shall continue for two years thereafter.

<After correction>

The exercise period shall commence on the date on which three years have elapsed from the day following the date of the resolution of the Board of Directors determining the subscription requirements of the Share Acquisition Rights, and shall continue for two years thereafter. (As the date of the resolution of the Board of Directors determining the subscription requirements is September 15, 2026, the exercise period shall be from September 16, 2029 to September 15, 2031.)

Other than the foregoing, there is no correction to (1) the resolutions for the issuance of the Share Acquisition Rights, (2) the purpose of introducing the stock option program and the reason for issuing the Share Acquisition Rights without payment of money, (3) the persons to be allotted the Share Acquisition Rights, the items of (4) other than those stated above, (5) the amount to be paid for the Share Acquisition Rights or the method of calculation thereof, (6) the value of the property to be contributed upon exercise of the Share Acquisition Rights, (8) the conditions for the exercise of the Share Acquisition Rights, (9) the grounds and conditions for the acquisition of the Share Acquisition Rights, (10) the restrictions on the transfer of the Share Acquisition Rights, (11) the matters concerning the increase in stated capital and capital reserve where shares are issued upon exercise of the Share Acquisition Rights, (12) the policy for the treatment of the Share Acquisition Rights in the event of a share exchange, share transfer or similar transaction, or (13) the treatment where certificates for the Share Acquisition Rights are issued.

End